NCT05432492已完成2 期
A Phase II Study of AK112 (PD-1/VEGF Bispecific) in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Akeso1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2022年8月3日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Objective Response Rate (ORR) Per mRECIST
研究概览
简要总结
Phase II open label, multicenter study to evaluate the efficacy and safety of AK112 (PD-1/VEGF Bispecific) in patients with unresectable hepatocellular carcinoma (HCC).
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures).
- •18 to 75 years old.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Have a life expectancy of at least 3 months.
- •BCLC stage B or C, not amenable to curative surgery.
- •Hepatocellular carcinoma confirmed by histology/cytology. Cirrhosis meets the clinical diagnostic criteria for hepatocellular carcinoma of the American Association for the Diagnosis of Liver Diseases (AASLD).
- •At least one measurable untreated lesion.
- •Child-Pugh class A.
- •Has adequate organ function.
- •All female and male subjects of reproductive potential must agree to use an effective method of contraception, as determined by the Investigator, during and for 120 days after the last dose of study treatment.
排除标准
- •With fibrous lamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma components in tumor tissues.
- •History of malignancy other than HCC within 5 years, except that basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
- •Have a history of hepatic encephalopathy or have a history of liver transplantation.
- •With clinical symptoms requires drainage of pleural effusion, ascites or pericardial effusion.
- •Central nervous system (CNS) metastasis or meningeal metastasis.
- •Prior immunotherapy with an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody (or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways).
- •Prior systemic bevacizumab and its analogues treatment.
- •Severe bleeding tendency or coagulation dysfunction; occurred arteriovenous thromboembolic events or bleeding events due to esophageal and/or gastric varices within 6 months before the first administration.
- •Known presence or history of required hormone treatment interstitial lung disease or non-infectious pneumonitis.
- •Has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- •Has undergone major surgery within 30 days prior to the first dose of study treatment.
- •History of myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or surgery within 12 months.
- •Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
研究组 & 干预措施
Cohort 1
Experimental
Subjects receive AK112 on Day 1 of every 3-week cycle (Q3W) until progression.
干预措施: AK112 (Drug)
Cohort 2
Experimental
Subjects receive AK112 on Day 1 of every 3-week cycle (Q3W) until progression.
干预措施: AK112 (Drug)
结局指标
主要结局
Objective Response Rate (ORR) Per mRECIST
时间窗: Up to approximately 2 years
Number of patients with Adverse Events (AEs)
时间窗: Up to approximately 2 years
Objective Response Rate (ORR) Per RECIST v1.1
时间窗: Up to approximately 2 years
次要结局
- Disease control rate (DCR)(Up to approximately 2 years)
- Overall survival (OS)(Up to approximately 2 years)
- Progression free survival (PFS)(Up to approximately 2 years)
- Duration of Response (DoR)(Up to approximately 2 years)
- Time to response (TTR)(Up to approximately 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of AK112 in Advanced Malignant TumorsAdvanced Malignant TumorsNCT05214482Akeso154
进行中（未招募）
1 期
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant TumorsAdvanced Malignant TumorsNCT05229497Akeso154
已完成
2 期
Study of AK112 in the Treatment of Advanced Gynecological TumorsGynecologic CancerCancer MetastaticOvarian NeoplasmsCervical NeoplasmEndometrial NeoplasmsNCT04870177Akeso53
招募中
1 期
A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)Hepatocellular CarcinomaNCT06530251Akeso280
进行中（未招募）
2 期
A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLCNSCLCNCT04736823Akeso265